Printer Friendly

Articles from M2 Pharma (October 2, 2019)

1-24 out of 24 article(s)
Title Author Type Words
AstraZeneca divests global commercial rights for Losec to Cheplapharm for USD243m. 289
Celltrion to launch Temixys in US. 131
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites. 362
Five Prime Therapeutics Presents Updated Data from the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 Congress. 436
FSD Pharma concludes first tranche of private placement for CAD4.583m. 206
Heron Therapeutics names new director. 237
Heron Therapeutics resubmits HTX-011 NDA to FDA for the management of postoperative pain. 198
Iksuda Therapeutics Presents First Data on Lead Antibody Drug Conjugate, Demonstrating Effective Tumour Regression. 295
ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin at ESMO. 385
INBUILD Meets Primary Endpoint. Study Evaluated Nintedanib in Patients Across a Range of Progressive Fibrosing Interstitial Lung Diseases. 389
Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer. 822
Luminex wins FDA 510(k) marketing clearance for the ARIES MRSA Assay. 219
Mayne Pharma enters into exclusive license and supply agreement for novel oral contraceptive E4/DRSP in the US. 319
Meditrina Inc announces USD13m from equity financing. 142
Merck meets primary endpoint in RESTORE-IMI two trial of RECARBRIO. 156
Merck's Keytruda Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer. 684
NOCD raises USD4m from Series A funding. 158
Novigenix's New Early Colon Cancer Detection Blood Test Demonstrates Positive Results. 488
Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of Braftovi, Mektovi and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer. 248
Preliminary Results from IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients with Advanced and Metastatic Solid Tumors Presented. 813
Senseonics awards equity grants to 16 new employees under inducement plan. 171
Servier acquires CTI BioPharma's Pixuvri. 163
The Pharmaceutical Research and Manufacturers of America names new executive vice president of policy and research. 179
X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma Patients. 849

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters